Medicare Part D drugs starting with J
28 drugs start with J; 12 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Jardiance in 2024: $11.4 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with J?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Jadenu (deferasirox) | under 0.1% | Tier 1 | $8 million |
| Jaimiess (ethinyl estradiol) | 68.5% | Tier 2 | $51 thousand |
| Jakafi (ruxolitinib) | 100% | Tier 5 | $2.1 billion |
| Jantoven (warfarin sodium) | 97.5% | Tier 1 | $3 million |
| Janumet (metformin hydrochloride / sitagliptin phosphate) | 94.8% | Tier 3 | $1.1 billion |
| Januvia (sitagliptin phosphate) | 100% | Tier 3 | $3.8 billion |
| Jardiance (empagliflozin) | 100% | Tier 3 | $11.4 billion |
| Jascayd (nerandomilast) | 6.2% | Tier 5 | no 2024 match |
| Jasmiel (drospirenone / ethinyl estradiol) | 91.1% | Tier 2 | $6 thousand |
| Jatenzo (testosterone undecanoate) | 0.1% | Tier 4 | $8 million |
| Javygtor (sapropterin dihydrochloride) | 34.2% | Tier 5 | $3 million |
| Jaypirca (pirtobrutinib) | 100% | Tier 5 | $201 million |
| Jaythari (deflazacort) | 15.4% | Tier 5 | no 2024 match |
| Jentadueto (linagliptin / metformin hydrochloride) | 87.6% | Tier 3 | $114 million |
| Jinteli (ethinyl estradiol / norethindrone acetate) | 66.2% | Tier 3 | $148 thousand |
| Joenja (leniolisib) | 3.1% | Tier 5 | $4 million |
| Journavx (suzetrigine) | 11.8% | Tier 4 | no 2024 match |
| Joyeaux (ethinyl estradiol / levonorgestrel) | 5.2% | Tier 3 | $12 thousand |
| Jubbonti (denosumab-bbdz) | 33.3% | Tier 4 | no 2024 match |
| Jublia (efinaconazole) | 19.2% | Tier 5 | $119 million |
| Juleber (desogestrel / ethinyl estradiol) | 93.7% | Tier 2 | $9 thousand |
| Juluca (dolutegravir / rilpivirine) | 100% | Tier 5 | $415 million |
| Junel (ethinyl estradiol / norethindrone acetate) | 92.9% | Tier 2 | $213 thousand |
| Junel Fe (ethinyl estradiol / norethindrone acetate) | 97.2% | Tier 2 | $417 thousand |
| Juxtapid (lomitapide) | 3.5% | Tier 5 | $7 million |
| Jylamvo (methotrexate) | 71.8% | Tier 4 | no 2024 match |
| Jynarque (tolvaptan) | 28.1% | Tier 5 | $103 million |
| Jynneos (mpox and smallpox vaccine) | 100% | Tier 1 | $338 thousand |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans